Top 5 Prefered Stocks To Watch For 2014

What's better than momentum? Mo' momentum. Let's take a closer look at five of this past week's biggest scorchers.

Company

June 7

Weekly Gain

Kandi Technologies (NASDAQ: KNDI  )

$5.69

52%

SodaStream (NASDAQ: SODA  )

$72.52

14%

MannKind (NASDAQ: MNKD  )

$7.46

12%

Boulder Brands (NASDAQ: BDBD  )

$11.65

11%

Northern Tier (NYSE: NTI  )

Hot Gold Companies To Own For 2015: Coronado Biosciences Inc (CNDO)

Coronado Biosciences, Inc., incorporated on June 28, 2006, is a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer. The Company�� two principal pharmaceutical product candidates in clinical development include Trichuris suis ova or CNDO-201 (TSO) a biologic comprising of the microscopic eggs of the porcine whipworm, for the treatment of autoimmune diseases, such as Crohn�� disease (Crohn��), ulcerative colitis (UC) and multiple sclerosis (MS), and CNDO-109, a compound that activates natural killer (NK) cells of the immune system to seek and destroy cancer cells, for the treatment of acute myeloid leukemia (AML). In January 2011, the Company acquired the OvaMed GmbH License.

TSO

TSO is the microscopic eggs of a parasitic helminth, or worm, that is found in pigs. In September 2011, the Company filed an Investigational New Drug Application (IND) with the United States Food and Drug Administration (FDA) and it initiated a single dose, dose escalation study in patients with Crohn�� in February 2012. The Phase 1 clinical trial was a multi-center, sequential dose-escalation, double-blind, placebo-controlled study, the primary objective of which was to evaluate the safety and tolerability of TSO. The trial enrolled 36 patients with Crohn�� ranging in age from 20 to 54 with an equal distribution of male and female patients in three single dose cohorts of orally administered 500, 2500 and 7500 ova. Each cohort had 12 patients, with nine patients receiving TSO and three receiving placebo.

CNDO-109

CNDO-109 is a lysate (disrupted CTV-1 cells, cell membrane fragments, cell proteins and other cellular components) that activates donor NK cells. CTV-1 is a leukemic cell line recently re-classified as a T-cell acute lymphocytic leukemia (ALL). The Company has worldwide rights to develop and commercialize CNDO-109 activated NK cells for the treatment of cancer fro! m UCLB. In February 2012, the Company submitted an IND for the CNDO-109 activated NK cell product in the United States. The treatment of patients with CNDO-109 activated NK cells involves several steps. The activated NK cells are infused into the patient after resting NK cells are incubated with CNDO-109 for at least eight hours. Preparation of CNDO-109 activated NK cells takes about 24 hours from start to finish.

The Company competes with Centocor Ortho Biotech Inc.�� Remicade , UCB S.A.�� Cimzia, Abbott Laboratories��Humira, Biogen Idec�� Avonex, Bayer Healthcare Pharmaceuticals��Betaseron, Teva Pharmaceuticals Industries, Ltd.�� Copaxone and Novartis AG�� Gilenya.

Advisors' Opinion:

• [By James E. Brumley]

  The last few weeks haven't been particularly encouraging for Crohn's disease sufferers. In August, GlaxoSmithKline (NYSE: GSK) and ChemoCentryx (NASDAQ:CCXI) reported that a jointly-developed Crohn's drug, vercirnon, had failed to meet its late-stage trial endpoints. Though the in-development drug isn't dead in the water (GSK and CCXI could rework the drug, the testing regimen, or use it for other indications), it doesn't look good. Then this month - just a few days ago - Coronado Biosciences Inc. (NASDAQ:CNDO) reported that its Phase 3 trials of Crohn's disease drug TSO had also failed to meet its primary endpoints as well. Like vercirnon, CNDO isn't completely out of luck here with the treatment, but forging ahead with further development of the treatment is grasping at straws. Crohn's sufferers don't need to give up home just yet, however - TNI Biotech Inc. (OTCMKTS:TNIB) appears to have a Crohn's treatment that works, and should be able to sidestep the problems that plagued ChemoCentryx, GlaxoSmithKline, and Coronado Biosciences.

Top 5 Prefered Stocks To Watch For 2014: Hilltop Holdings Inc. (HTH)

Hilltop Holdings Inc., through its subsidiary, NLASCO, Inc., operates as a property and casualty insurance company in the United States. The company�s personal product line includes homeowners, dwelling fire, manufactured home, flood, and vacant insurance policies; and commercial product line consists of commercial, builders risk, builders risk renovation, sports liability, and inland marine insurance policies. It distributes its insurance products through a network of independent agents and managing general agents. The company was formerly known as Affordable Residential Communities Inc. and changed its name to Hilltop Holdings Inc. in July 2007. Hilltop Holdings Inc. was founded in 1948 and is headquartered in Dallas, Texas.

Advisors' Opinion:

• [By Jake L'Ecuyer]

  Meanwhile, top decliners in the sector included Tree.Com (NASDAQ: TREE), down 4.7 percent, and Hilltop Holdings (NYSE: HTH), off 6.7 percent.

  Top Headline
  Office Depot (NYSE: ODP) reported upbeat first-quarter results and announced its plans to close at least 400 stores in the United States. For the full year, Office Depot also lifted its adjusted operating income outlook to at least $160 million versus $140 million. Office Depot posted a quarterly net loss of $109 million, or $0.21 per share, versus a year-ago loss of $17 million, or $0.06 per share.

• [By Lauren Pollock]

  Hilltop Holdings Inc.(HTH) offered to buy the rest of SWS Group Inc.(SWS) that it doesn’t already own, valuing the financial-services company at about $231 million. Hilltop, a regional banking and insurance company, offered $7 a share, a 16% premium over Thursday’s close. SWS surged 19% to $7.20 premarket,�topping the offer price.

Top 5 Prefered Stocks To Watch For 2014: Mylan Inc (MYL)

Mylan Inc. (Mylan), incorporated in 1970, is a pharmaceutical company, which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. The Company operates a specialty business, which is focused on respiratory, allergy and psychiatric therapies. Through Mylan Laboratories Limited, an Indian subsidiary, it manufactures and supply active pharmaceutical ingredient (API) for its own products and pipeline, as well as for third parties. On December 23, 2011, Mylan completed the acquisition of rights to develop, manufacture and commercialize a generic equivalent to GlaxoSmithKline�� Advair Diskus and Seretide Diskus incorporating Pfizer Inc.��, (Pfizer) dry powder inhaler delivery platform (the Respiratory Delivery Platform). In February 2012, Valeant Pharmaceuticals International, Inc. announced that it has completed the divestiture of 1% clindamycin and 5% benzoyl peroxide gel (IDP-111), a generic version of Benzaclin, and 5% fluorouracil cream, (5-FU), an authorized generic of Efudex, to the Company.

As of December 31, 2011, Mylan marketed a global portfolio of approximately 1,100 different products covering a range of therapeutic categories. It offers a range of dosage forms and delivery systems, including oral solids, topicals, liquids and semi-solids. In addition, it focuses on transdermal patches, high potency formulations, injectables, controlled release and respiratory delivery products. Mylan operates in two segments: Generics and Specialty. Its revenues are derived from the sale of generic and branded generic pharmaceuticals, specialty pharmaceuticals and API. Its generic pharmaceutical business is conducted in the United States and Canada (collectively, North America); Europe, the Middle East, and Africa (collectively, EMEA), and India, Australia, Japan and New Zealand (collectively, Asia Pacific). Its API business is conducted through Mylan Laboratories Limited, which is included within the Asia Pacific region in its Generi! cs segment. Its specialty pharmaceutical business is conducted by Dey Pharma, L.P. (Dey).

Generics Segment

The Company sales in the United States are derived through its wholly owned subsidiary Mylan Pharmaceuticals Inc. (MPI), its primary United States pharmaceutical research, development, manufacturing, marketing and distribution subsidiary, as well as through Mylan Institutional (MI). MPI�� net revenues are derived from the sale of solid oral dosage and transdermal patch products. MI�� net revenues are derived from the sale of its unit dose and injectable product offerings. In the United States, it has product portfolios consisting of approximately 340 products, of which approximately 305 are in capsule or tablet form in an aggregate of approximately 740 dosage strengths. Included in these totals are approximately 40 extended release products in a total of approximately 105 dosage strengths. Also included in it�� the United States product portfolio are four transdermal patch products in a total of 18 dosage strengths, which are developed and manufactured by Mylan Technologies, Inc. (MTI), its wholly owned transdermal technology subsidiary, and marketed and distributed by MPI.

The Company�� North America revenues also include those generated by its wholly owned subsidiary Mylan Pharmaceuticals ULC (MPC), which markets generic pharmaceuticals in Canada. MPC offers a portfolio of approximately 115 products in an aggregate of approximately 250 dosage strengths. Its generic pharmaceutical sales in EMEA are generated by its wholly owned subsidiaries in Europe, through which it has operations in 21 countries.

In France, through the Company�� subsidiary Mylan S.A.S., it markets a retail portfolio of approximately 215 products in an aggregate of approximately 455 dosage strengths. In Italy, it markets through its subsidiary Mylan S.p.A. a portfolio of approximately 150 products in an aggregate of approximately 285 dosage strengths. In Italy, it h! as market! share, based on value and volume, in the company-branded generic retail prescription market. In Spain, it markets through its subsidiary Mylan Pharmaceuticals S.L. a portfolio of approximately 100 products in an aggregate of approximately 220 dosage strengths. In Germany, it markets through its subsidiary Mylan dura a portfolio of approximately 150 products in an aggregate of approximately 330 dosage strengths. In the United Kingdom, it offers a product portfolio of approximately 175 products in an aggregate of approximately 315 dosage strengths. It markets generic pharmaceuticals in Asia Pacific through subsidiaries in Australia, New Zealand, India, Japan and Taiwan.

In Australia, the Company offers a portfolio of approximately 170 products in an aggregate of approximately 440 dosage strengths. Mylan Seiyaku, its wholly owned Japanese subsidiary, offers a portfolio of more than 380 products in an aggregate of approximately 500 dosage strengths. At Mylan Laboratories Limited, its dosage business produces antiretroviral (ARV) products, which are sold outside of India, and other finished dosage form (FDF) products, which are sold to third parties by other Mylan operations globally. In addition, Mylan Laboratories Limited offers a line of FDF products in the ARV market and manufactures non-ARV FDF products that are marketed by Mylan.

Specialty Segment

The Company�� specialty pharmaceutical business is conducted through Dey. Dey�� portfolio consists of branded specialty injectable, nebulized and transdermal products for life-threatening conditions. Dey�� revenues are derived through the sale of the EpiPen Auto-Injector. The EpiPen Auto-Injector, which is used in the treatment of severe allergic reactions, is an epinephrine auto-injector that has been sold in the United States and internationally.

Advisors' Opinion:

• [By Diane Alter]

  Statin drugs are already a profitable niche in the drug market. But the biggest winners will be makers of lower-priced generics. Those include Mylan Labs (MYL) and Teva Pharmaceuticals (TEVA).

• [By Jon C. Ogg]

  Mylan Inc. (NASDAQ: MYL) is also in generics and projected to be a considering a broad range of assets and deals. The note here is that a transaction needs to have a strategic rationale, and not solely for tax or cost synergy reasons. The company wants to make sure that it must maintain its investment grade credit rating and that any deal needs to be accretive to earnings. Potential transactions are benchmarked against repurchasing securities here. Mylan was shown to have done four deals in the past decade worth almost $10 billion, and its current market cap is almost $17 billion.

• [By Ben Levisohn]

  Since Friday, three major acquisitions have been announced. AECOM Technology�(ACM) said it would buy URS�(URS) for $4 billion; Mylan�(MYL) agreed to pay $5.3 billion for�Abbott Laboratories�(ABT) non-U.S. generic drug business; and Whiting Petroleum (WLL) said it would take over Kodiak Oil & Gas (KOG). And amazingly, none of them appear to be overpriced.

• [By MONEYMORNING.COM]

  The challenge is in finding a stock that has established a strong track record but still has room to grow. The big generics makers, like Teva Pharmaceuticals Industries Ltd. (NYSE ADR: TEVA), (Sandoz) Novartis AG (NYSE ADR: NVS), and Mylan Inc. (Nasdaq: MYL), sport market caps in the many billions of dollars. They've already seen most of their upside- particularly now, with fewer patents closing out next year.

Top 5 Prefered Stocks To Watch For 2014: Decision Diagnostics Corp (DECN)

Decision Diagnostics Corp., formerly instaCare Corp., incorporated on March 2, 2001, is a prescription and non-prescription diagnostics and home testing products distributor. The Company distributes brand name prescription and non-prescription diagnostics products, as well as several lines of ostomy, wound cares and post-surgery medical products. The Company through its subsidiaries, PDA Services, Inc. and Decision IT Corp. offers information technology solutions in several medical cares market channels by providing physicians with information at the point of care. The Company's retail prescription business maintains three operating units, which include Licensed wholesale prescription drug distribution business; Licensed distribution of diabetes diagnostics and supplies; and Internet pharmacy/prescription fulfillment.

The Company's software is designed to integrate point of service applications. The Company is also a developer of products that offer solutions in medical care and management by providing physicians with essential information instantaneously as they meet with their patients. In addition, the Company markets its MD@Hand and MD @Work software application, which also leverages the connectivity of smart cell phones devices through the Internet. The Company's applications run on smart phones manufactured by Apple, Palm, Motorola and Samsung.

Advisors' Opinion:

• [By Bryan Murphy]

  Over the past few weeks, Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) and Decision Diagnostics Corp. (OTCBB:DECN) have dominated the diabetes diagnostics and diabetes treatment landscape. Shares of LXRX jumped 20% on Tuesday following news that one of the key drugs in its pipeline showed more than enough efficacy in its clinical trials. DECN shares are up more than 250% on the heels of an almost-assured victory in its patent lawsuit against industry giant Johnson & Johnson (NYSE:JNJ). Anyone looking for a new trade in the diabetes diagnostics space, however, may want to look past overbought Lexicon Pharmaceuticals and Decision Diagnostics at this point, and instead turn their attention to newly-budding Neurometrix Inc. (NASDAQ:NURO).